Ovarian cancer clinical trials

Explore recruiting ovarian cancer clinical trials.

Recruiting ovarian cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ovarian cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

Austria, Finland, Czechia, Italy, Germany, Ireland +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

Netherlands, Spain, Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

CHIPOR : Randomized phase III study evaluating hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)

Spain, Czechia, France, Belgium, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Spain, Sweden, Netherlands, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

IMPROCAS - Improved Prediction of Ovarian Cancer Surgery

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Ovarian cancer trials by city

Ovarian cancer in Toronto Ovarian cancer in Vancouver Ovarian cancer in Montreal Ovarian cancer in Calgary Ovarian cancer in Edmonton Ovarian cancer in Ottawa Ovarian cancer in Winnipeg Ovarian cancer in Quebec City Ovarian cancer in Hamilton Ovarian cancer in Kitchener Ovarian cancer in London Ovarian cancer in Halifax Ovarian cancer in New York Ovarian cancer in Los Angeles Ovarian cancer in Chicago Ovarian cancer in Houston

Other conditions

Endometriosis Uterine fibroids Menopause Infertility Erectile dysfunction Enlarged prostate (BPH) Breast cancer Prostate cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Melanoma Leukemia Lymphoma Multiple myeloma Bladder cancer Kidney cancer Liver cancer Glioblastoma Head and neck cancer Cervical cancer Endometrial cancer Gastric cancer